市場調查報告書

2020-2027年全球口服抗生素市場的類別,用途,藥物來源,活動範圍,藥物類型-機會分析和行業預測

Oral Antibiotics Market, by Class, Application, Drug Origin, Spectrum Of Activity, Drug Type : Global Opportunity Analysis and Industry Forecast, 2020-2027

出版商 Allied Market Research 商品編碼 951410
出版日期 內容資訊 英文 329 Pages
商品交期: 2-3個工作天內
價格
2020-2027年全球口服抗生素市場的類別,用途,藥物來源,活動範圍,藥物類型-機會分析和行業預測 Oral Antibiotics Market, by Class, Application, Drug Origin, Spectrum Of Activity, Drug Type : Global Opportunity Analysis and Industry Forecast, 2020-2027
出版日期: 2020年06月01日內容資訊: 英文 329 Pages
簡介

2018年,全球口服抗生素市場規模達到183.658億美元。在2019年至2027年之間,市場預計將以2.7%的複合年增長率增長,到2027年預計將達到233.661億美元。低收入和中等收入國家(LMIC)的高消費和傳染病的流行正在推動對抗生素的需求。此外,開髮用於治療細菌感染的新抗生素的新方法以及大量的臨床試驗正在進一步推動市場增長。另外,用於治療抗藥性微生物感染的先進分子和新型聯合療法的發現有望為市場參與者提供大量的收入機會。但是,由於濫用抗生素以及需要經過監管部門批准而導致的抗生素耐藥性的發展預計會阻礙市場的增長。

本報告調查了全球口服抗生素市場,包括市場機會和影響,增長和限制,類別/用途/藥物來源/活性譜,藥物類型/區域市場分析和競爭。提供了有關主要公司的狀況和概況的信息。

內容

第1章簡介

第2章執行摘要

第3章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資產品
    • 成功策略
  • 市場佔有率分析
  • 波特的五力分析
  • 市場動態
    • 生長因子
      • 中低收入國家(LMIC)的消費增加
      • 傳染病患病率上升
      • 開發新方法
    • 抑制因子
      • 抗生素耐藥性的發展
      • 耗時的批准
    • 市場機會
      • 發現用於治療抗生素耐藥性的先進療法
  • COVID-19對口服抗生素市場的影響分析

第4章市場分析:按類別

  • 概述
    • 市場規模和分類預測
  • BETA-內□胺和BETA-內□胺□抑製劑
    • 青黴素
    • 頭孢菌素
    • 其他
  • 奎諾酮
  • 大環內酯
  • 其他

第5章市場分析:按用途

  • 概述
    • 市場規模和預測
  • 社區傳播的呼吸道感染(CARTIs)
    • 上呼吸道感染(URTI)
    • 下呼吸道感染(LRTI)
  • 尿路感染(UTI)
  • 牙科
    • 組合
    • 單藥治療
  • 其他

第6章市場分析按藥品來源劃分

  • 概述
    • 市場規模和預測
  • 自然
  • 半合成
  • 合成

第7章按活動範圍分析市場

  • 概述
    • 市場規模和預測
  • 廣譜抗生素
  • 中/窄範圍抗生素

第8章藥品類型的市場分析

  • 概述
    • 市場規模和預測
  • 品牌
  • 通用

第9章市場分析:按地區

  • 概述
    • 市場規模和預測
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲/中東/非洲

第10章公司簡介

  • ABBOTT LABORATORIES
  • ALLERGAN PLC
  • F. HOFFMANN-LA ROCHE LTD.
  • GLAXOSMITHKLINE PLC
  • MERCK & CO., INC.
  • MYLAN N.V.
  • NOVARTIS INTERNATIONAL AG (PEAR THERAPEUTICS, INC.)
  • PFIZER INC.
  • SANOFI
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
目錄
Product Code: A06540

Title:
Oral Antibiotics Market, by Class (Beta lactam & beta lactamase inhibitors, Quinolones, Macrolide, and Others), Application (Community-Acquired Respiratory Tract Infections (CARTIS), Urinary Tract Infections (UTIS), Dental, and Others), Drug Origin (Natural, Semisynthetic, Synthetic), Spectrum Of Activity (Broad-Spectrum Antibiotic, Mid/Narrow-Spectrum Antibiotic), Drug Type (Branded And Generics): Global Opportunity Analysis and Industry Forecast, 2020-2027.

The global oral antibiotics market generated $18,365.80 million in 2018, and is projected to reach $23,306.10 million by 2027, growing at a CAGR of 2.7% from 2019 to 2027.

Antibiotic is an antimicrobial substance or a compound that fights against bacterial infections and sometimes with protozoan infections, but not viral infections. These are medications that either stop bacteria from growing or kill bacteria directly, referred as bacteriostatic and bactericidal antibiotics, respectively. There are several types of antibiotics easily available at drug stores and in hospitals with a prescription or without a prescription in most of countries. Antibiotics are mostly used during transplants, dialysis, suppressed immune system, and joint replacement.

There is an increase in demand for antibiotics, owing to increased consumption in low- and middle-income countries (LMICs) and rise in prevalence of infectious diseases. In addition, development of novel approaches for new antibiotics to treat bacterial infections and large number of clinical trials further drive the market growth. However, development of antibiotic resistance, driven by misuse of antibiotics and time taken for regulatory approvals are projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players.

The global oral antibiotics market is segmented on the basis of class, application drug origin, spectrum of activity, application, and region. On the basis of class, the market is classified into beta lactam & beta lactamase inhibitors, quinolones, macrolides, and others. Beta lactam & beta lactamase inhibitors is further segmented into Penicillin, Cephalosporin, and others. By application, the market is divided into community- respiratory tract infections (CARTIS), urinary acquired tract infections (UTIS), dental, and others. Depending on drug origin, it is categorized into natural, semisynthetic, and synthetic. According to the spectrum of activity, it is bifurcated into broad-spectrum antibiotic and narrow-spectrum antibiotic. By drug type, it is divided into branded and generics. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

Depending on class, the market is categorized into Beta lactam & beta lactamase inhibitors, Quinolones, Macrolide, and Others. The beta lactam & beta lactamase inhibitors segment was the highest contributor to the market in 2018. The segment is a major revenue contributor, owing to its broad-spectrum of activity A broad-spectrum antibiotic fights both Gram-negative and Gram-positive bacteria as well as effective on the multiple groups of bacterial infections.

On the basis of application, the oral antibiotics market is classified into community-acquired respiratory tract infections (CARTIs), urinary tract infections (UTIs), dental, and others. The CARTIs segment is further segmented into upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTI). The dental segment is further divided into combination and monotherapies.

On the basis of drug origin, the oral antibiotics market is classified into natural, semisynthetic, and synthetic. The synthetic segment generated highest revenue in 2018, and is anticipated to maintain its dominance throughout the forecast period. This is attributed to the fact that semisynthetic oral antibiotics have improved coverage and effectiveness against a wide range of organisms.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global oral antibiotics market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers market analysis from 2020 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global oral antibiotics market growth.

KEY MARKET SEGMENTS

By Class

  • Beta Lactam and Beta Lactamase Inhibitors
  • Penicillin
  • Broad Spectrum Penicillin
  • Mid/Narrow Spectrum Penicillin
  • Cephalosporin
  • Others
  • Quinolone
  • Macrolide
  • Others

By Application

  • Community-respiratory tract infections (CARTIS)
  • Upper Respiratory Tract Infections (URTI)
  • Lower Respiratory Tract Infections (LRTI)
  • Urinary acquired tract infections (UTIS)
  • Dental
  • Combination
  • Monotherapies
  • Others

By Drug Origin

  • Natural
  • Semisynthetic
  • Synthetic

By Spectrum of Activity

  • Broad-spectrum Antibiotic
  • Narrow-spectrum Antibiotic

By Drug Type

  • Branded
  • Generic

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • Spain
  • Italy
  • UK
  • Russia
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • India
  • China
  • Pakistan
  • Vietnam
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Turkey
  • Rest of LAMEA
  • List of key players profiled in the report
  • Abbott Laboratories
  • Allergan Plc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Mylan N.V.
  • Novartis International AG (Sandoz)
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
    • 2.1.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Market share analysis, 2018
  • 3.4.Porter's five forces analysis
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Increase in consumption in low-and middle-income countries (LMICs)
      • 3.5.1.2.Rise in prevalence of infectious diseases
      • 3.5.1.3.Development of novel approaches
    • 3.5.2.Restraints
      • 3.5.2.1.Development of antibiotic resistance
      • 3.5.2.2.Time consuming approvals
    • 3.5.3.Opportunities
      • 3.5.3.1.Discovery of advanced therapies to treat antibiotic-resistance.
  • 3.6.Impact analysis of COVID-19 on oral antibiotics market

CHAPTER 4:ORAL ANTIBIOTICS MARKET, BY CLASS

  • 4.1.Overview
    • 4.1.1.Market size and forecast, by class
  • 4.2.Beta lactam and beta lactamase inhibitors
    • 4.2.1.Key market trends and growth opportunities
    • 4.2.2.Market size and forecast, by type
      • 4.2.2.1.Penicillin
      • 4.2.2.1.1.Market size and forecast, by type
      • 4.2.2.1.1.1.Broad-spectrum penicillin
      • 4.2.2.1.1.2.Mid/Narrow-spectrum penicillin
      • 4.2.2.2.Cephalosporin
      • 4.2.2.2.1.Market size and forecast
      • 4.2.2.2.2.Market size and forecast, by molecule
      • 4.2.2.3.Others
      • 4.2.2.3.1.Market size and forecast
    • 4.2.3.Market size and forecast, by region
    • 4.2.4.Market analysis, by country
  • 4.3.Quinolones
    • 4.3.1.Key market trends and growth opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
  • 4.4.Macrolides
    • 4.4.1.Key market trends and growth opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country
  • 4.5.Others
    • 4.5.1.Key market trends and growth opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country

CHAPTER 5:ORAL ANTIBIOTICS MARKET, BY APPLICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Community-acquired respiratory tract infections (CARTIs)
    • 5.2.1.Market size and forecast, by type
      • 5.2.1.1.Upper Respiratory Tract Infections (URTI)
      • 5.2.1.1.1.Market size and forecast
      • 5.2.1.1.2.Market size and forecast, by molecule
      • 5.2.1.2.Lower Respiratory Tract Infections (LRTIs)
      • 5.2.1.2.1.Market size and forecast
      • 5.2.1.2.2.Market size and forecast, by molecule
    • 5.2.2.Market size and forecast, by region
    • 5.2.3.Market analysis, by country
  • 5.3.Urinary tract infections (UTIs)
    • 5.3.1.Market size and forecast, by molecule
    • 5.3.2.Market size and forecast, by region
    • 5.3.3.Market analysis, by country
  • 5.4.Dental
    • 5.4.1.Market size and forecast, by type
      • 5.4.1.1.Combination
      • 5.4.1.1.1.Market size and forecast
      • 5.4.1.1.2.Market size and forecast, by molecule
      • 5.4.1.2.Monotherapies
      • 5.4.1.2.1.Market size and forecast
      • 5.4.1.2.2.Market size and forecast, by molecule
    • 5.4.2.Market size and forecast, by region
    • 5.4.3.Market analysis, by country
  • 5.5.Others
    • 5.5.1.Market size and forecast, by region
    • 5.5.2.Market analysis, by country

CHAPTER 6:ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Natural
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Semisynthetic
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country
  • 6.4.Synthetic
    • 6.4.1.Market size and forecast, by region
    • 6.4.2.Market analysis, by country

CHAPTER 7:ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.Broad-spectrum antibiotic
    • 7.2.1.Market size and forecast, by region
    • 7.2.2.Market analysis, by country
  • 7.3.Mid/Narrow-spectrum antibiotic
    • 7.3.1.Market size and forecast, by region
    • 7.3.2.Market analysis, by country

CHAPTER 8:ORAL ANTIBIOTICS MARKET, BY DRUG TYPE

  • 8.1.Overview
    • 8.1.1.Market size and forecast
  • 8.2.Branded
    • 8.2.1.Market size and forecast, by region
    • 8.2.2.Market analysis, by country
  • 8.3.Generics
    • 8.3.1.Market size and forecast, by region
    • 8.3.2.Market analysis, by country

CHAPTER 9:ORAL ANTIBIOTICS MARKET, BY REGION

  • 9.1.Overview
    • 9.1.1.Market size and forecast
  • 9.2.North America
    • 9.2.1.Key market trends and opportunities
    • 9.2.2.North America antibiotics market, by country
      • 9.2.2.1.U.S. oral antibiotics market, by class
      • 9.2.2.2.U.S. oral antibiotics market, by application
      • 9.2.2.3.U.S. oral antibiotics market, by drug origin
      • 9.2.2.4.U.S. oral antibiotics market, by spectrum of activity
      • 9.2.2.5.U.S. oral antibiotics market, by Drug type
      • 9.2.2.6.Canada oral antibiotics market, by class
      • 9.2.2.7.Canada oral antibiotics market, by application
      • 9.2.2.8.Canada oral antibiotics market, by drug origin
      • 9.2.2.9.Canada oral antibiotics market, by spectrum of activity
      • 9.2.2.10.Canada oral antibiotics market, by drug type
      • 9.2.2.11.Mexico oral antibiotics market, by class162
      • 9.2.2.12.Mexico oral antibiotics market, by application
      • 9.2.2.13.Mexico oral antibiotics market, by drug origin
      • 9.2.2.14.Mexico oral antibiotics market, by spectrum of activity
      • 9.2.2.15.Mexico oral antibiotics market, by drug type
    • 9.2.3.North America oral antibiotics market, by class
    • 9.2.4.North America oral antibiotics market, by application
    • 9.2.5.North America oral antibiotics market, by drug origin
    • 9.2.6.North America oral antibiotics market, by spectrum of activity
    • 9.2.7.North America antibiotics market, by drug type
  • 9.3.Europe
    • 9.3.1.Key market trends and opportunities
    • 9.3.2.Europe oral antibiotics market, by country
      • 9.3.2.1.Germany oral antibiotics market, by class
      • 9.3.2.2.Germany oral antibiotics market, by application
      • 9.3.2.3.Germany oral antibiotics market, by drug origin
      • 9.3.2.4.Germany oral antibiotics market, by spectrum of activity
      • 9.3.2.5.Germany oral antibiotics market, by Drug type
      • 9.3.2.6.France oral antibiotics market, by class
      • 9.3.2.7.France oral antibiotics market, by application
      • 9.3.2.8.France oral antibiotics market, by drug origin
      • 9.3.2.9.France oral antibiotics market, by spectrum of activity
      • 9.3.2.10.France oral antibiotics market, by drug type
      • 9.3.2.11.Spain oral antibiotics market, by class181
      • 9.3.2.12.Spain oral antibiotics market, by application
      • 9.3.2.13.Spain oral antibiotics market, by drug origin
      • 9.3.2.14.Spain oral antibiotics market, by spectrum of activity
      • 9.3.2.15.Spain oral antibiotics market, by drug type
      • 9.3.2.16.Italy oral antibiotics market, by class185
      • 9.3.2.17.Italy oral antibiotics market, by application
      • 9.3.2.18.Italy oral antibiotics market, by drug origin
      • 9.3.2.19.Italy oral antibiotics market, by spectrum of activity
      • 9.3.2.20.Italy oral antibiotics market, by drug type
      • 9.3.2.21.UK oral antibiotics market, by class
      • 9.3.2.22.UK oral antibiotics market, by application
      • 9.3.2.23.UK oral antibiotics market, by drug origin
      • 9.3.2.24.UK oral antibiotics market, by spectrum of activity
      • 9.3.2.25.UK oral antibiotics market, by drug type
      • 9.3.2.26.Russia oral antibiotics market, by class
      • 9.3.2.27.Russia oral antibiotics market, by application
      • 9.3.2.28.Russia oral antibiotics market, by drug origin
      • 9.3.2.29.Russia oral antibiotics market, by spectrum of activity
      • 9.3.2.30.Russia oral antibiotics market, by drug type
      • 9.3.2.31.Rest of Europe oral antibiotics market, by class
      • 9.3.2.32.Rest of Europe oral antibiotics market, by application
      • 9.3.2.33.Rest of Europe oral antibiotics market, by drug origin
      • 9.3.2.34.Rest of Europe oral antibiotics market, by spectrum of activity
      • 9.3.2.35.Rest of Europe oral antibiotics market, by drug type
    • 9.3.3.Europe oral antibiotics market, by class
    • 9.3.4.Europe oral antibiotics market, by application
    • 9.3.5.Europe oral antibiotics market, by drug origin
    • 9.3.6.Europe oral antibiotics market, by spectrum of activity
    • 9.3.7.Europe oral antibiotics market, by drug type
  • 9.4.Asia-Pacific
    • 9.4.1.Key market trends and opportunities
    • 9.4.2.Asia-Pacific oral antibiotics market, by country
      • 9.4.2.1.Japan oral antibiotics market, by class
      • 9.4.2.2.Japan oral antibiotics market, by application
      • 9.4.2.3.Japan oral antibiotics market, by drug origin
      • 9.4.2.4.Japan oral antibiotics market, by spectrum of activity
      • 9.4.2.5.Japan oral antibiotics market, by drug type
      • 9.4.2.6.India oral antibiotics market, by class
      • 9.4.2.7.India oral antibiotics market, by application
      • 9.4.2.8.India oral antibiotics market, by drug origin
      • 9.4.2.9.India oral antibiotics market, by spectrum of activity
      • 9.4.2.10.India oral antibiotics market, by drug type
      • 9.4.2.11.China oral antibiotics market, by class
      • 9.4.2.12.China oral antibiotics market, by application
      • 9.4.2.13.China oral antibiotics market, by drug origin
      • 9.4.2.14.China oral antibiotics market, by spectrum of activity
      • 9.4.2.15.China oral antibiotics market, by drug type
      • 9.4.2.16.Pakistan oral antibiotics market, by class
      • 9.4.2.17.Pakistan oral antibiotics market, by application
      • 9.4.2.18.Pakistan oral antibiotics market, by drug origin
      • 9.4.2.19.Pakistan oral antibiotics market, by spectrum of activity
      • 9.4.2.20.Pakistan oral antibiotics market, by Drug type
      • 9.4.2.21.Vietnam oral antibiotics market, by class
      • 9.4.2.22.Vietnam oral antibiotics market, by application
      • 9.4.2.23.Vietnam oral antibiotics market, by drug origin
      • 9.4.2.24.Vietnam oral antibiotics market, by spectrum of activity
      • 9.4.2.25.Vietnam oral antibiotics market, by Drug type
      • 9.4.2.26.Rest of Asia-Pacific oral antibiotics market, by class
      • 9.4.2.27.Rest of Asia-Pacific oral antibiotics market, by application
      • 9.4.2.28.Rest of Asia-Pacific oral antibiotics market, by drug origin
      • 9.4.2.29.Rest of Asia-Pacific oral antibiotics market, by spectrum of activity
      • 9.4.2.30.Rest of Asia-Pacific oral antibiotics market, by drug type
    • 9.4.3.Asia-Pacific oral antibiotics market, by class
    • 9.4.4.Asia-Pacific oral antibiotics market, by application
    • 9.4.5.Asia-Pacific oral antibiotics market, by drug origin
    • 9.4.6.Asia-Pacific oral antibiotics market, by spectrum of activity
    • 9.4.7.Asia-Pacific oral antibiotics market, by drug type
  • 9.5.LAMEA
    • 9.5.1.Key market trends and opportunities
    • 9.5.2.LAMEA antibiotics market, by country
      • 9.5.2.1.Brazil oral antibiotics market, by class
      • 9.5.2.2.Brazil oral antibiotics market, by application
      • 9.5.2.3.Brazil oral antibiotics market, by drug origin
      • 9.5.2.4.Brazil oral antibiotics market, by spectrum of activity
      • 9.5.2.5.Brazil oral antibiotics market, by drug type
      • 9.5.2.6.Saudi Arabia oral antibiotics market, by class
      • 9.5.2.7.Saudi Arabia oral antibiotics market, by application
      • 9.5.2.8.Saudi Arabia oral antibiotics market, by drug origin
      • 9.5.2.9.Saudi Arabia oral antibiotics market, by spectrum of activity
      • 9.5.2.10.Saudi Arabia oral antibiotics market, by application
      • 9.5.2.11.South Africa oral antibiotics market, by class
      • 9.5.2.12.South Africa oral antibiotics market, by application
      • 9.5.2.13.South Africa oral antibiotics market, by drug origin
      • 9.5.2.14.South Africa oral antibiotics market, by spectrum of activity
      • 9.5.2.15.South Africa oral antibiotics market, by drug type
      • 9.5.2.16.Turkey oral antibiotics market, by class
      • 9.5.2.17.Turkey oral antibiotics market, by application
      • 9.5.2.18.Turkey oral antibiotics market, by drug origin
      • 9.5.2.19.Turkey oral antibiotics market, by spectrum of activity
      • 9.5.2.20.Turkey oral antibiotics market, by drug type
      • 9.5.2.21.Rest of LAMEA oral antibiotics market, by class
      • 9.5.2.22.Rest of LAMEA oral antibiotics market, by application
      • 9.5.2.23.Rest of LAMEA oral antibiotics market, by drug origin
      • 9.5.2.24.Rest of LAMEA oral antibiotics market, by spectrum of activity
      • 9.5.2.25.Rest of LAMEA oral antibiotics market, by drug type
    • 9.5.3.LAMEA antibiotics market, by class
    • 9.5.4.LAMEA antibiotics market, by application
    • 9.5.5.LAMEA antibiotics market, by drug origin
    • 9.5.6.LAMEA antibiotics market, by spectrum of activity
    • 9.5.7.LAMEA antibiotics market, by drug type

CHAPTER 10:COMPANY PROFILES

  • 10.1.ABBOTT LABORATORIES
    • 10.1.1.Company overview
    • 10.1.2.Company snapshot
    • 10.1.3.Operating business segments
    • 10.1.4.Product portfolio
    • 10.1.5.Business performance
  • 10.2.ALLERGAN PLC
    • 10.2.1.Company overview
    • 10.2.2.Company snapshot
    • 10.2.3.Operating business segments
    • 10.2.4.Product portfolio
    • 10.2.5.Business performance
    • 10.2.6.Key strategic moves and developments
  • 10.3.F. HOFFMANN-LA ROCHE LTD.
    • 10.3.1.Company overview
    • 10.3.2.Company snapshot
    • 10.3.3.Operating business segments
    • 10.3.4.Product portfolio
    • 10.3.5.Business performance
    • 10.3.6.Key strategic moves and developments
  • 10.4.GLAXOSMITHKLINE PLC
    • 10.4.1.Company overview
    • 10.4.2.Company snapshot
    • 10.4.3.Operating business segments
    • 10.4.4.Product portfolio
    • 10.4.5.Business performance
    • 10.4.6.Key strategic moves and developments
  • 10.5.MERCK & CO., INC.
    • 10.5.1.Company overview
    • 10.5.2.Company snapshot
    • 10.5.3.Operating business segments
    • 10.5.4.Product portfolio
    • 10.5.5.Business performance
    • 10.5.6.Key strategic moves and developments
  • 10.6.MYLAN N.V.
    • 10.6.1.Company overview
    • 10.6.2.Company snapshot
    • 10.6.3.Operating business segments
    • 10.6.4.Product portfolio
    • 10.6.5.Business performance
    • 10.6.6.Key strategic moves and developments
  • 10.7.NOVARTIS INTERNATIONAL AG (PEAR THERAPEUTICS, INC.)
    • 10.7.1.Company overview
    • 10.7.2.Company snapshot
    • 10.7.3.Operating business segments
    • 10.7.4.Product portfolio
    • 10.7.5.Business performance
    • 10.7.6.Key strategic moves and developments
  • 10.8.PFIZER INC.
    • 10.8.1.Company overview
    • 10.8.2.Company snapshot
    • 10.8.3.Operating business segments
    • 10.8.4.Operating Product
    • 10.8.5.Business performance
    • 10.8.6.Key strategic moves and developments
  • 10.9.SANOFI
    • 10.9.1.Company overview
    • 10.9.2.Company snapshot
    • 10.9.3.Operating business segments
    • 10.9.4.Product portfolio
    • 10.9.5.Business performance
    • 10.9.6.Key strategic moves and developments
  • 10.10.TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 10.10.1.Company overview
    • 10.10.2.Company snapshot
    • 10.10.3.Operating business segments
    • 10.10.4.Product portfolio
    • 10.10.5.Business performance

LIST OF TABLES

  • TABLE 01.GLOBAL ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 02.BETA LACTAM & BETA LACTAMASE INHIBITORS ANTIBIOTICS MARKET, BY TYPE, 2018-2027 ($MILLION)
  • TABLE 03.PENICILLIN ORAL ANTIBIOTICS MARKET, BY TYPE, 2018-2027 ($MILLION)
  • TABLE 04.ORAL ANTIBIOTICS MARKET FOR CEPHALOSPORIN, BY MOLECULE, 2018-2027 ($MILLION)
  • TABLE 05.ANTIBIOTICS MARKET FOR BETA LACTAM AND BETA LACTAMASE INHIBITORS, BY REGION, 2018-2027 ($MILLION)
  • TABLE 06.ANTIBIOTICS MARKET FOR QUINOLONES, BY REGION, 2018-2027 ($MILLION)
  • TABLE 07.ANTIBIOTICS MARKET FOR MACROLIDES, BY REGION, 2018-2027 ($MILLION)
  • TABLE 08.ANTIBIOTICS MARKET FOR OTHER CLASSES BY REGION, 2018-2027 ($MILLION)
  • TABLE 09.GLOBAL ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 10.ORAL ANTIBIOTICS MARKET FOR COMMUNITY-ACQUIRED RESPIRATORY TRACT INFECTIONS, BY TYPE, 2018-2027 ($MILLION)
  • TABLE 11.ORAL ANTIBIOTICS MARKET FOR UPPER RESPIRATORY TRACT INFECTIONS, BY MOLECULE, 2018-2027 ($MILLION)
  • TABLE 12.ORAL ANTIBIOTICS MARKET FOR LOWER RESPIRATORY TRACT INFECTIONS, BY MOLECULE, 2018-2027 ($MILLION)
  • TABLE 13.ORAL ANTIBIOTICS MARKET FOR COMMUNITY-ACQUIRED RESPIRATORY TRACT INFECTIONS, BY REGION, 2018-2027 ($MILLION)
  • TABLE 14.ORAL ANTIBIOTICS MARKET FOR URINARY TRACT INFECTIONS, BY MOLECULE, 2018-2027 ($MILLION)
  • TABLE 15.ORAL ANTIBIOTICS MARKET FOR URINARY TRACT INFECTIONS, BY REGION, 2018-2027 ($MILLION)
  • TABLE 16.ORAL ANTIBIOTICS MARKET FOR DENTAL, BY TYPE, 2018-2027 ($MILLION)
  • TABLE 17.ORAL ANTIBIOTICS MARKET FOR DENTAL COMBINATION ORAL ANTIBIOTICS, BY MOLECULE, 2018-2027 ($MILLION)
  • TABLE 18.ORAL ANTIBIOTICS MARKET FOR DENTAL MONOTHERAPIES, BY MOLECULE, 2018-2027 ($MILLION)
  • TABLE 19.ORAL ANTIBIOTICS MARKET FOR DENTAL, BY REGION, 2018-2027 ($MILLION)
  • TABLE 20.ORAL ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 2018-2027 ($MILLION)
  • TABLE 21.GLOBAL ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 22.ORAL ANTIBIOTICS MARKET FOR NATURAL, BY REGION, 2018-2027 ($MILLION)
  • TABLE 23.ORAL ANTIBIOTICS MARKET FOR SEMISYNTHETIC, BY REGION, 2018-2027 ($MILLION)
  • TABLE 24.ORAL ANTIBIOTICS MARKET FOR SYNTHETIC, BY REGION, 2018-2027 ($MILLION)
  • TABLE 25.GLOBAL ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 26.ORAL ANTIBIOTICS MARKET FOR BROAD-SPECTRUM ORAL ANTIBIOTIC, BY REGION, 2018-2027 ($MILLION)
  • TABLE 27.ORAL ANTIBIOTICS MARKET FOR MID/NARROW-SPECTRUM ORAL ANTIBIOTIC, BY REGION, 2018-2027 ($MILLION)
  • TABLE 28.GLOBAL ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 29.BRANDED ANTIBIOTICS MARKET, BY REGION, 2018-2027 ($MILLION)TABLE 30.GENERIC ANTIBIOTICS MARKET, BY REGION, 2018-2027 ($MILLION)
  • TABLE 31.ORAL ANTIBIOTICS MARKET REVENUE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 32.NORTH AMERICA ANTIBIOTICS MARKET, BY COUNTRY, 2018-2027 ($MILLION)
  • TABLE 33.U.S. ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 34.U.S. ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 35.U.S. ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 36.U.S. ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 37.U.S. ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 38.CANADA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 39.CANADA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 40.CANADA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 41.CANADA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 42.CANADA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 43.MEXICO ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 44.MEXICO ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 45.MEXICO ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 46.MEXICO ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 47.MEXICO ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 48.NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 49.NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 50.NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 51.NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 52.NORTH AMERICA ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 53.EUROPE ORAL ANTIBIOTICS MARKET, BY COUNTRY, 2018-2027 ($MILLION)
  • TABLE 54.GERMANY ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 55.GERMANY ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 56.GERMANY ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 57.GERMANY ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 58.GERMANY ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 59.FRANCE ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 60.FRANCE ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 61.FRANCE ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 62.FRANCE ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 63.FRANCE ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 64.SPAIN ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 65.SPAIN ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 66.SPAIN ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 67.SPAIN ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 68.SPAIN ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 69.ITALY ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 70.ITALY ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 71.ITALY ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 72.ITALY ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 73.ITALY ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 74.UK ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 75.UK ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 76.UK ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 77.UK ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 78.UK ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 79.RUSSIA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 80.RUSSIA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 81.RUSSIA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 82.RUSSIA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 83.RUSSIA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 84.REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 85.REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 86.REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 87.REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 88.REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 89.EUROPE ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 90.EUROPE ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 91.EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 92.EUROPE ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 93.EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 94.ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY COUNTRY, 2018-2027 ($MILLION)
  • TABLE 95.JAPAN ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 96.JAPAN ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 97.JAPAN ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 98.JAPAN ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 99.JAPAN ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 100.INDIA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 101.INDIA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 102.INDIA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 103.INDIA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 104.INDIA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 105.CHINA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 106.CHINA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 107.CHINA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 108.CHINA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 109.CHINA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 110.PAKISTAN ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 111.PAKISTAN ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 112.PAKISTAN ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 113.PAKISTAN ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 114.PAKISTAN ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 115.VIETNAM ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 116.VIETNAM ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 117.VIETNAM ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 118.VIETNAM ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 119.VIETNAM ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 120.REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 121.REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 122.REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 123.REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 124.REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 125.ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 126.ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 127.ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 128.ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 129.ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 130.LAMEA ANTIBIOTICS MARKET, BY COUNTRY, 2018-2027 ($MILLION)
  • TABLE 131.BRAZIL ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 132.BRAZIL ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 133.BRAZIL ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 134.BRAZIL ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 135.BRAZIL ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 136.SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 137.SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 138.SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 139.SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 140.SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 141.SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 142.SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 143.SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 144.SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 145.SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 146.TURKEY ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 147.TURKEY ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 148.TURKEY ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 149.TURKEY ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 150.TURKEY ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 151.REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 152.REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 153.REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 154.REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 155.REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 156.LAMEA ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
  • TABLE 157.LAMEA ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
  • TABLE 158.LAMEA ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION)
  • TABLE 159.LAMEA ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION)
  • TABLE 160.LAMEA ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
  • TABLE 161.ABBOTT: COMPANY SNAPSHOT
  • TABLE 162.ABBOTT: OERATING SEGMENT
  • TABLE 163.ABBOTT: PRODUCT PORTFOLIO
  • TABLE 164.ALLERGAN: COMPANY SNAPSHOT
  • TABLE 165.ALLERGAN: OPERATING SEGMENTS
  • TABLE 166.ALLERGAN: PRODUCT PORTFOLIO
  • TABLE 167.ROCHE: COMPANY SNAPSHOT
  • TABLE 168.ROCHE: OERATING SEGMENT
  • TABLE 169.ROCHE: PRODUCT PORTFOLIO
  • TABLE 170.GSK: COMPANY SNAPSHOT
  • TABLE 171.GSK: OPERATING SEGMENTS
  • TABLE 172.GSK: PRODUCT PORTFOLIO
  • TABLE 173.MERCK: COMPANY SNAPSHOT
  • TABLE 174.MERCK: OPERATING SEGMENTS
  • TABLE 175.MERCK PRODUCT PORTFOLIO
  • TABLE 176.MYLAN: COMPANY SNAPSHOT
  • TABLE 177.MYLAN: OPERATING SEGMENTS
  • TABLE 178.ALLERGAN: PRODUCT PORTFOLIO
  • TABLE 179.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 180.NOVARTIS: OPERATING SEGMENTS
  • TABLE 181.NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 182.PFIZER: COMPANY SNAPSHOT
  • TABLE 183.PFIZER: OPERATING SEGMENTS
  • TABLE 184.PFIZER: PRODUCT PORTFOLIO
  • TABLE 185.SANOFI: COMPANY SNAPSHOT
  • TABLE 186.SANOFI: OPERATING SEGMENTS
  • TABLE 187.SANOFI: PRODUCT PORTFOLIO
  • TABLE 188.TEVA: COMPANY SNAPSHOT
  • TABLE 189.TEVA: OPERATING SEGMENTS
  • TABLE 190.TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.ORAL ANTIBIOTICS MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS IN THE GLOBAL ORAL ANTIBIOTICS MARKET
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017-2020*
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017-2020* (%)
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017-2020*
  • FIGURE 06.MARKET SHARE ANALYSIS, 2018
  • FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 08.HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 09.LOW THREAT OF NEW ENTRANTS
  • FIGURE 10.MODERATE THREAT OF SUBSTITUTIONS
  • FIGURE 11.HIGH COMPETITIVE RIVALRY
  • FIGURE 12.BROAD-SPECTRUM PENICILLIN MARKET, 2018-2027 ($MILLION)
  • FIGURE 13.MID/NARROW-SPECTRUM PENICILLIN MARKET, 2018-2027 ($MILLION)
  • FIGURE 14.CEPHALOSPORIN ANTIBIOTICS MARKET, 2018-2027 ($MILLION)
  • FIGURE 15.OTHER BETA LACTAM & BETA LACTAMASE INHIBITORS ANTIBIOTICS MARKET, 2018-2027 ($MILLION)
  • FIGURE 16.COMPARATIVE ANALYSIS OF ANTIBIOTICS MARKET FOR BETA LACTAM AND BETA LACTAMASE INHIBITORS, BY COUNTRY, 2018 & 2027 ($MILLION)
  • FIGURE 17.COMPARATIVE ANALYSIS OF ANTIBIOTICS MARKET FOR QUINOLONES, BY COUNTRY, 2018 & 2027 ($MILLION)
  • FIGURE 18.COMPARATIVE ANALYSIS OF ANTIBIOTICS MARKET FOR MACROLIDES, BY COUNTRY, 2018 & 2027 ($MILLION)
  • FIGURE 19.COMPARATIVE ANALYSIS OF ANITBIOTICS MARKET FOR OTHERS, BY COUNTRY, 2018 & 2027 ($MILLION)
  • FIGURE 20.ORAL ANTIBIOTICS MARKET FOR UPPER RESPIRATORY TRACT INFECTIONS, 2018-2027 ($MILLION)
  • FIGURE 21.ORAL ANTIBIOTICS MARKET FOR LOWER RESPIRATORY TRACT INFECTIONS, 2018-2027 ($MILLION)
  • FIGURE 22.COMPARATIVE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR COMMUNITY-ACQUIRED RESPIRATORY TRACT INFECTIONS, BY COUNTRY, 2018 & 2027 ($MILLION)
  • FIGURE 23.COMPARATIVE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR URINARY TRACT INFECTIONS, BY COUNTRY, 2018 & 2027 ($MILLION)
  • FIGURE 24.ORAL ANTIBIOTICS MARKET FOR DENTAL, BY COMBINATION, 2018-2027 ($MILLION)
  • FIGURE 25.ORAL ANTIBIOTICS MARKET FOR DENTAL, BY MONOTHERAPIES, 2018-2027 ($MILLION)
  • FIGURE 26.COMPARATIVE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR DENTAL, BY COUNTRY, 2018 & 2027 ($MILLION)
  • FIGURE 27.COMPARATIVE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR OTHERS, BY COUNTRY, 2018 & 2027 ($MILLION)
  • FIGURE 28.COMPARATIVE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR NATURAL, BY COUNTRY, 2018 & 2027 ($MILLION)
  • FIGURE 29.COMPARATIVE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR SEMISYNTHETIC, BY COUNTRY, 2018 & 2027 ($MILLION)
  • FIGURE 30.COMPARATIVE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR SYNTHETIC, BY COUNTRY, 2018 & 2027 ($MILLION)
  • FIGURE 31.COMPARATIVE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR BROAD-SPECTRUM ORAL ANTIBIOTIC, BY COUNTRY, 2018 & 2027 ($MILLION)
  • FIGURE 32.COMPARATIVE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR MID/NARROW-SPECTRUM ORAL ANTIBIOTIC, BY COUNTRY, 2018 & 2027 ($MILLION)
  • FIGURE 33.COMPARATIVE ANALYSIS OF BRANDED ORAL ANTIBIOTICS MARKET, BY COUNTRY, 2018 & 2027 ($MILLION)
  • FIGURE 34.COMPARATIVE ANALYSIS OF GENERIC ORAL ANTIBIOTICS MARKET, BY COUNTRY, 2018 & 2027 ($MILLION)
  • FIGURE 35.ABBOTT: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 36.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 37.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 38.ALLERGAN: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 39.ALLERGAN: REVENUE SHARE, BY SEGMENT, 2019(%)
  • FIGURE 40.ROCHE: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 41.ROCHE: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 42.ROCHE: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 43.GSK: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 44.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 45.GSK: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 46.MERCK: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 47.MERCK: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 48.MERCK: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 49.MYLAN: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 50.MYLAN: REVENUE SHARE, BY REGION, 2017 (%)
  • FIGURE 51.NOVARTIS: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 52.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 53.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 54.PFIZER: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 55.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 56.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 57.SANOFI: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 58.SANOFI: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 59.SANOFI: REVENUE SHARE, BY REGION, 2019(%)
  • FIGURE 60.TEVA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 61.TEVA: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 62.TEVA: REVENUE SHARE, BY REGION, 2019 (%)